RxDoctor Payments DataLook up a doctor →

Melissa Alsina, MD

Hematology · Tampa, FLNPI 1184656746

Payments from drug & device makers

$12,965,956in general payments, 2019–2025

Across 234 payments — averaging $55,410 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$5M
  • Amgen$4.2M
  • Pfizer$2.6M
  • Janssen Research & Development, LLC$736K
  • AstraZeneca$347K
  • E.r. Squibb & Sons, L.L.C.$98K
  • plus $45K from 12 others

What the payments were for

  • Consulting fees$47,56774%
  • Speaking & faculty fees$10,60017%
  • Travel & lodging$2,3234%
  • Food & beverage$3,3955%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,965,956 in reported general payments places this provider in the 95th percentile of 79 hematology providers in Florida.

See all hematology providers in Florida

Medicare billing

Part B allowed, 2024
$42,065
Medicare patients
181
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide111$1,970,880
Lenalidomide132$1,795,595
PomalystPomalidomide73$1,572,435
NinlaroIxazomib Citrate14$180,680
Atovaquone13$3,582
Acyclovir146$1,777
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim22$308
Prochlorperazine Maleate13$204
Dexamethasone14$186
Tramadol Hcl22$167
Oxycodone Hcl22$102
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$100
Lorazepam11$17

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$4,998,598$1,970,880111 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$98,276$1,572,43573 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$3,095$180,68014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 hematology providers in Florida.

Other hematology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →